Intravitreal bevacizumab for macular complications from retinal arterial macroaneurysms

Francesco Pichi, Mariachiara Morara, Carlo Torrazza, Gianluigi Manzi, Micol Alkabes, Nicole Balducci, Lucia Vitale, Andrea Lembo, Antonio P. Ciardella, Paolo Nucci

Research output: Contribution to journalArticlepeer-review


Purpose: To evaluate the anatomic and functional results of the treatment with intravitreal bevacizumab in complicated retinal arterial macroaneurysm (RAM). Design: A multicenter interventional, prospective, nonrandomized study. Methods: Thirty-eight macroaneurysms of 37 patients with foveal complications were evaluated. All patients underwent a comprehensive ophthalmologic examination, fluorescein angiography (FA), and spectral-domain optical coherence tomography (SD OCT) examination. Each patient underwent 3 monthly injections of bevacizumab 1.25 mg/0.05 mL; 3 follow-up visits were planned at week 2, 6, and 12. Results: Both best-corrected visual acuity (BCVA), expressed in logarithm of minimal angle of resolution (logMAR), and central retinal thickness (CRT) significantly improved during the follow-up visits (0.57 ± 0.21 vs 0.41 ± 0.15 vs 0.23 ± 0.13 vs 0.09 ± 0.10 and 520.38 ± 191.05 vs 396.24 ± 136.18 vs 283.86 ± 71.87 vs 214.84 ± 26.86, respectively, Friedman test P

Original languageEnglish
JournalAmerican Journal of Ophthalmology
Issue number2
Publication statusPublished - Feb 2013

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Intravitreal bevacizumab for macular complications from retinal arterial macroaneurysms'. Together they form a unique fingerprint.

Cite this